Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 7541-7550 Newer>

The Motley Fool May 25, 2005 Stephen D. Simpson	Investors Juiced About Scottish Power Selling the disappointing PacifiCorp utility to Berkshire Hathaway sparks investor enthusiasm.
The Motley Fool May 25, 2005	Behold the Income Statement The income statement is easy -- and important -- to understand.
The Motley Fool May 25, 2005 Rick Aristotle Munarriz	Do You Love Your Mamma? It's getting harder and harder these days for investors to love search engine specialist Mamma.com.
The Motley Fool May 24, 2005 Will Ashworth	Guitar Center Makes Beautiful Music Guitar Center helps musicians of all capabilities to become better ones, while producing a handsome profit. As for its current stock price, it's valued similarly to its peers. Return on equity is 20%, compared with 14% for the industry as a whole.
The Motley Fool May 24, 2005 Jeff Hwang	Red Flags: 3 Signs a Stock May Crash Like traffic accidents, investing accidents occur more frequently than we would like to think. If you are holding the wrong stocks, it's time to change lanes.
The Motley Fool May 24, 2005 Rich Smith	JDS Uniphase Buys Something Will Acterna help the telecom play grow, or sink it? It's a pricey acquisition, even at a cost that's just over half the price-to-sales ratio JDS shares currently fetch.
The Motley Fool May 24, 2005 W.D. Crotty	11-Bagger's Wings Clipped Chicken processor Sanderson Farms reports lower revenue and earnings, but cash and high margins provide a comfy cushion.
The Motley Fool May 24, 2005 Alyce Lomax	Putting the Sparkle in Online Sales Some investors may take heart in the growth projections for online sales of jewelry.
The Motley Fool May 24, 2005 Rich Smith	Lifeway Finds Its Target The deal with Target takes the kefir maker one step closer to nationwide recognition of its product. And since recognition is a prerequisite to making a sale, and making a sale a prerequisite to making a profit on that sale, this is good news for shareholders.
The Motley Fool May 24, 2005 Charly Travers	Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note.
<Older 7541-7550 Newer> Return to current articles.